Patent details

EP3310760 Title: CRYSTALLINE L-ARGININE SALT OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLO-PENTA[B]INDOL-3-YL)ACETIC ACID FOR USE IN S1P1 RECEPTOR-ASSOCIATED DISORDERS

Basic Information

Publication number:
EP3310760
PCT Application Number:
US2016038506
Type:
European Patent Granted for LU
Legal Status:
In force
Application number:
EP167345297
PCT Publication Number:
WO2016209809
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
CRYSTALLINE L-ARGININE SALT OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLO-PENTA[B]INDOL-3-YL)ACETIC ACID FOR USE IN S1P1 RECEPTOR-ASSOCIATED DISORDERS
French Title of Invention:
SEL L-ARGININE CRISTALLIN D'ACIDE (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMÉTHYL)BENZYLOXY)-1,2,3,4-TÉTRAHYDROCYCLO-PENTA[B]INDOL-3-YL)ACÉTIQUE POUR UNE UTILISATION DANS DES TROUBLES ASSOCIÉS AU RÉCEPTEUR DE S1P1
German Title of Invention:
KRISTALLINES L-ARGININSALZ VON (R) -2-(7-(4-CYCLOPENTYL-3-(TRIFLUORMETHYL) BENZYLOXY ) -1,2,3,4-TETRAHYDROCYCLO-PENTA [ B ] INDOL-3-YL) ESSIGSÄURE ZUR VERWENDUNG BEI S1P1-REZEPTOR-ASSOZIERTEN ERKRANKUNGEN
SPC Number:

Dates

Filing date:
21/06/2016
Grant date:
14/09/2022
EP Publication Date:
25/04/2018
PCT Publication Date:
29/12/2016
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
14/09/2022
EP B1 Publication Date:
14/09/2022
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
21/06/2036
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
10/03/2023
 
 

Name:
Arena Pharmaceuticals, Inc.
Address:
66 Hudson Boulevard East, New York, NY 10001-2192, United States (US)

History of Owners

From:
07/09/2022
To:
02/09/2022

Name:
Arena Pharmaceuticals, Inc.
Address:
6154 Nancy Ridge Drive, San Diego, CA 92121, United States (US)

From:
02/09/2022
To:
10/03/2023

Name:
Arena Pharmaceuticals, Inc.
Address:
235 East 42nd Street, New York, NY 10017, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
07/10/2022
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Inventor

1

Name:
HADD, Mark A.
Address:
United States (US)

2

Name:
CASTRO, Ryan O.
Address:
United States (US)

3

Name:
MA, You-An
Address:
United States (US)

4

Name:
SELVEY, Lee Alani
Address:
United States (US)

5

Name:
CARLOS, Marlon
Address:
United States (US)

6

Name:
BLACKBURN, Anthony C.
Address:
United States (US)

7

Name:
SHAKYA, Sagar Raj
Address:
United States (US)

8

Name:
MONTALBAN, Antonio Garrido
Address:
United States (US)

9

Name:
RUETER, Jaimie Karyn
Address:
United States (US)

Priority

1

Priority Number:
201562182841 P
Priority Date:
22/06/2015
Priority Country:
United States (US)

2

Priority Number:
201562207531 P
Priority Date:
20/08/2015
Priority Country:
United States (US)

Classification

IPC classification:
C07D 209/94; A61K 31/403; A61P 37/00; A61P 29/00; A61P 35/00; A61P 9/00; A61P 1/00; A61P 7/00; A61P 3/00; A61P 5/00;

Publication

European Patent Bulletin

1

Issue number:
202237
Publication date:
14/09/2022
Description:
Grant (B1)

2

Issue number:
202242
Publication date:
19/10/2022
Description:
Document reprinted after correction (B8, B9)

3

Issue number:
202315
Publication date:
12/04/2023
Description:
Change of owner's name or address

4

Issue number:
202240
Publication date:
05/10/2022
Description:
Change of owner's name or address

Annual Fees

Annual Fee Due Date:
30/06/2025
Annual Fee Number:
10
Annual Fee Amount:
131 Euro
Expected Payer:
Last Annual Fee Payment Date:
14/05/2024
Last Annual Fee Paid Number:
9
Last Annual Fee Paid Amount:
115 Euro
Payer:
MASTER DATA CENTER INC (ex Clarivate Analytics)
Filing date Document type Number of pages
07/10/2022 Power Of Attorney 1
07/10/2022 Outgoing Correspondence 1